The dream of any organ procurement organization is to achieve self-sufficiency, where the number of organs needed is met by an equal number of organs available. In 2023, we can hope to reach selfsufficiency by providing kidneys to most patients in terminal renal failure. This can be achieved by decreasing the demand since SGL2 inhibitors have shown promising results in delaying renal failure. On the other hand, progress in the development of the bioartificial kidney and advances in xenotransplantation will significantly increase the number of organs offered.